Suppression of the acute inflammatory response of porcine alveolar- and liver macrophages

Veterinary Quarterly

Volumn 22, Issue 1, 2000, Pages 26-30

  Izeboud, C A ^a,b   Monshouwer, M ^c   Witkamp, R F ^a,b   van Miert, A S J P A M ^b  

^a TNO   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c PFIZER INC   (United States)

Author keywords

Inflammation; LPS; Macrophages; Porcine; TNF

Indexed keywords

ANIMAL CELL; ANIMAL DISEASE; ARTICLE; IMMUNE RESPONSE; LIVER METABOLISM; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN;

ANIMALS; CELL CULTURE TECHNIQUES; CYTOKINES; INFLAMMATION; LIPOPOLYSACCHARIDES; LIVER; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; RECEPTORS, ADRENERGIC, BETA; SWINE;

ANIMALIA; MAMMALIA; SUIDAE;

EID: 0033956568     PISSN: 01652176     EISSN: 18755941     Source Type: Journal    
DOI: 10.1080/01652176.2000.9695019     Document Type: Article

References (42)

1. Asari Y, Majima M, Sugimoto K, Katori M, and Ohwada T. Release site of TNF-a after intavenous and intraperitoneal injection of LPS from Escherichia coli in rats. Shock 1996; 5 (3): 208–12.
2. Beutler B, and Kruys V. Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signalling by tumor necrosis factor itself. J Cardiovasc Pharm 1995; 25 (2): s1–8.
3. Butchers PR, Vardey CJ, and Johnson M. Salmeterol, a potent and longacting inhibitor of inflammatory mediator release from human lung. Br Pharmacol 1991; 104: 627–76.
4. Carlson TJ, and Billings RE. Role of nitric oxide in the cytokine mediated regulation of cytochrome p-450. Mol Pharmacol 1996; 49: 796–801.
5. Cheng JB, Watson JW, Pazoles CJ, Eskra JD, Griffiths RJ, Cohan VL, Turner CR, Showell HJ, and Pettipher ER. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-a (TNF) production in mice: effect of adrenalectomy. J Pharmacol Exp Ther 1996; 280: 621–6.
6. Clark MA, Bing BA, Gottschall PE, and Williams JA. Differential effect of cytokines on the phenobarbital or 3-methylcholantrene induction of p450 mediated monooxygenase activity in cultured rat hepatocytes. Biochem Pharmacol 1995; 49 (1): 97–104.
7. Cruijsen TL, Leengoed LA van, Dekker-Nooren TC, Schoevers EJ, and Verheijden JH. Phagocytosis and killing of Actinobacillus pleuropneumoniae by alveolar macrophages and polymorphonuclear leukocytes isolated from pigs. Infect Immun 1992; 60 (11): 4867–71.
8. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem 1990; 192: 245–61.
9. Decker K. The response of liver macrophages to inflammatory stimulation. Keio J Med 1998; 47 (1): 1–9.
10. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, and Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukocyte Biol 1998; 63: 101–7.
11. Freudenberg MA, and Galanos C. The metabolic fate of endotoxins Prog Clin Biol Res 1988; 272: 63–75.
12. Gu Y, and Seidel A. Influence of salbutamol and isoproterenol on the production of TNF and reactive oxygen species by bovine alveolar macrophages and calcitrol differentiated HL-60 cells. Immunopharm Immunot 1996; 18 (1): 115–28.
13. Hahn PY, Yoo P, Ba ZF, Chaudry IH, and Wang P. Upregulation of kupffer cell beta-adrenoceptors and camp levels during the late stage of sepsis. Biochim Biophys Acta 1998; 1404 (3): 377–84.
14. Haskó G, Nemeth ZH, Szabó C, Zsilla G, Salzman AL, and Vizi ES. Isoproterenol inhibits IL-10, TNF-a, and nitric oxideproduction in RAW 264.7 macrophages. Brain Res Bull 1998; 45 (2): 183–7.
15. Henderson B, Poole S, and Wilson M. Bacterial modulins; a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Microbiol Rev 1996; 60 (2): 316–41.
16. Hetier E, Ayala J, Bousseau A, and Prochiantz A. Modulation of interleukin-1 and tumor necrosis factor expression by B-adrenergic agonists in mouse amoeboid microglial cells. Exp Brain Res 1991; 86: 407–13.
17. Hoebe KHN, Monshouwer M, Witkamp RF, Fink-Gremmels J, and Miert ASJPAM van. Cocultures of porcinehepatocytes and Kupffer cells as an improved in vitro model for the study of hepatotoxic compounds. Vet Quart; 2000; 22: 21–5.
18. Izeboud CA, Mocking JAJ, Monshouwer M, Miert ASJPAM van, and Witkamp RF. Participation of B-adrcnergicreceptors on macrophages in modulation of LPS-induced cytokine release. J Recept Signal Transduct Res 1999; 19 (1-4): 191–202.
19. Izeboud CA, Monshouwer M, Miert ASJPAM van, and Witkamp RF. The B-adrenoceptor agonist clenbuterol is a potent inhibitor of the LPSinduced production of TNF-a and IL-6 in vitro and in vivo. Inflamm Res 1999; 48: 497–502.
20. Leist M, Auer Barth S, Wendel A. Tumor necrosis factor production in the perfused mouse liver and its pharmacological modulation by methylxanthines. J Pharmacol Exp Ther 1996; 276 (3): 968–76.
21. Leist M, Gantner F, Jilg S, and Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol 1995; 154: 1307–16.
22. Monshouwer M, Witkamp RF, Nijmeijer SM, Pijpers A, Verheijden JH, and Miert ASJPAM van. Selective effects of a bacterial infection (Actinobacillus pleuropneumoniae) on the hepatic clearances of caffeine, antipyrine, paracetamol, and indocyanine green in the pig. Xenobiotica 1995; 25 (5): 491–9.
23. Monshouwer M, Witkamp RF, Nijmeijer SM, Amsterdam JG van, and Miert ASJPAM van. Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primarycultures of pig hepatocytes. Toxicol Appl Pharmacol 1996; 137 (2): 237–44.
24. Monshouwer M, Witkamp RF, Nijmeijer SM, Leengoed LA van, Verheijden JH, and Miert ASJPAM van. Infection (Actinobacillus pleuropneumoniae)-mediated suppression of oxidative hepatic drug metabolism and cytochrome P4503A mRNA levels in pigs. Drug Metab Dispos 1995: 23 (1): 44–7.
25. Monshouwer M, Witkamp RF, Nijmeijer SM, Van Leengoed LA, Vemooy HC, Verheijden JH, van Miert AS. A lipopolysaccharide-induced acute phase response in the pig is associated with a decrease in hepatic cytochrome P450-mediated drug metabolism. J Vet Pharmacol Ther 1996; 19 (5): 382–8.
26. Muntané Relat J, Ourlin JC, Domergue J, and Maurel P. Differential effects of cytokines on the inducible expression of CYP1A 1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995; (4 Pt 1)1143–53.
27. Parillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471–7.
28. Pauli U. Porcine TNF: a review. Vet Immunol Immunopathol 1995; 47 (3-4): 187–201.
29. Radojcic T, Baird S, Darko D, Smith D, Bulloch K. Changes in 13-adrenergic receptor distribution on immunocytes during differentiation: an analysis of T-cells and macrophages. J Neurosci Res 1991; 30: 328–35.
30. Redl H, Bahrami S, Schlag G, Traber DL. Clinical detection of LPS and animal models of endotoxemia. Immunobiol 1993;187:330–45.
31. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976; 13: 29–83.
32. Sekut L, Champion BR, Page K, Menius jr. JA, Conolly KM. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin Exp Immunol 1995; 99: 461–6.
33. Seldon PM, Barnes PJ, Meja K, and Giembycz MA. Suppression of lipopolysaccharide-induced tumor necrosis factor-a generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. J Pharmacol Exp Ther 1995; 48: 747–57.
34. Sewer MB, Koop DR, and Morgan ET. Endotoximia in rats is associated with induction of the P4504A subfamily andsuppression of several other forms of cytochrome P450. Drug Metab Dispos 1996;24(4):401–7.
35. Smedsrod B, and Pertoft H. Preparation ofpure hepatocytes and reticuloendothelial cells in high yield from a single rat liver by means of percoll centrifugation and selective adherence. J Leukocyte Biol 1985; 38: 213–30.
36. Stricter RM, Kunkel SL, and Bone RC. Role of tumor necrosis factor-a alpha in disease states and inflammation. Crit Care Med 1993; 21 (10 Suppl): S447–63.
37. Szabo C, Hasid G, Zingarelli B, Németh ZH, Salzman AL, Kvetan V, Mccarthy Pastores S, and Vizi ES. Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology 1997; 90: 95–100.
38. Tracey KJ, and Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491–503.
39. Van der Poll T, Jansen J, Leenen D van, Möhlen M van der, Levi M, Ten Cate H, Gallati H, Catel W ten, and Deventer SJH van. Release of soluble receptors for tumor necrosis factor in clinical and experimental endotoxemia. J Infect Dis 1993; 168: 955–60.
40. Van Miert ASJPAM. Pro-inflammatory cytokines in a ruminant model: pathophysiological, pharmacological, and therapeutic aspects. Vet Quart 1995; 17 (2): 41–50.
41. Van Miert ASJPAM. Influence of febrile disease on the pharmacokinetics of veterinary drugs. Ann Rech Vet 1990; 21: 11s-28s.
42. Yao YM, Redl H, Bahrami S, and Schlag G. The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm Res 1998; 47 (5): 201–10.